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Introduction {#sec1}
============

Type I interferons (IFNs) regulate diverse cellular functions by modulating the expression of a large family of IFN-stimulated genes (ISGs) through the activation of the Janus kinase (JAK) and signal transducers and activators of transcription (STAT) proteins ([@bib21], [@bib46]). ISGs subsequently influence multiple pathways involved in cell stress responses, apoptosis, and proliferation and mediate diverse immune effects ([@bib17], [@bib18]). The potent immune response elicited by IFNs is exemplified by the establishment of an antiviral state that enabled their original discovery ([@bib25]). This state relies on the induction and activation of numerous intrinsic antiviral factors, most notably the Mx GTPases, the 2′-5′-oligoadenylate-synthetase (OAS) system, ISG15, and protein kinase R (PKR) ([@bib39]). In addition, IFNs modulate distinct aspects of both innate and adaptive immunity, affecting the activities of macrophages, natural killer (NK) cells, dendritic cells, and T cells by enhancing ISG expression profiles, cell differentiation, cell trafficking, and antigen presentation. Because of the numerous effects of IFNs, they have been used therapeutically against a variety of diseases, including viral infections, immunomodulatory disorders, and hematological and solid tumors ([@bib6]). The factors determining the outcome of IFN treatment, however, are not understood, and IFN therapy has had variable success. Although the essential JAK-STAT signal transduction pathway is well characterized, recent studies have revealed greater complexity in patterns of gene induction than initially envisaged ([@bib9], [@bib49], [@bib53]). Here, we identified an IFN-mediated signal that leads to activation of the promyelocytic leukemia zinc finger protein (PLZF, encoded by *Zbtb16*) transcription factor that has fundamental consequences for the immune response.

PLZF is a member of the "BTB-POZ" (bric á brac, tramtrack, broad complex-poxvirus zinc finger) family of transcription factors and represses genes by recruiting several different corepressor complexes. Two recent reports describe a role for PLZF in the immune response as a transcription factor that is necessary for full function of natural killer T (NKT) cells ([@bib27], [@bib40]), although the mechanisms were not investigated. Here, we present evidence that the role of PLZF in the immune response is broader than described in these reports. Contrary to the previous designation of PLZF as a repressor of transcription, we showed that PLZF was required for the induction of a subset of ISGs that are crucial in the ensuing immune response via the induction of the antiviral genes and other ISG functions, including NK cell activity. These findings provide new insights into the regulation of IFN-mediated immunity.

Results {#sec2}
=======

PLZF Regulates Sensitivity to IFN {#sec2.1}
---------------------------------

To determine the factors contributing to IFN sensitivity, we analyzed two renal cancer cell lines, differing markedly in their response to IFN ([@bib23]), for their ISG profiles. Higher and more persistent expression of a subset of ISGs was noted in the IFN-sensitive RCC1 cells when compared with the relatively IFN-insensitive ACHN cells ( [Figure 1](#fig1){ref-type="fig"}A). Correspondingly, RCC1 cells showed an increased IFN-mediated antiviral response ([Figure S1](#app2){ref-type="sec"} available online). No differences in established IFN-regulatory factors were apparent between the two cell lines ([@bib23]). Therefore, to account for the differential regulation of this subset of ISGs, we analyzed the promoter proximal regions (1000 bp upstream of the ATG) for features that distinguished these genes from other ISGs that were synchronous between the two cell lines. It was found that genes differentially induced by IFNα treatment in the RCC1 cells exhibited an overrepresentation of DNA-binding motifs for the PLZF protein ([Table S1](#app2){ref-type="sec"}). Cluster analysis showed the putative PLZF-binding sites were in proximity to sites occupied by essential STAT and IFN regulatory factors (IRFs), increasing the likelihood that these motifs were biologically relevant ([Figure S2](#app2){ref-type="sec"}). To test this correlation between expression of ISGs with putative binding motifs and expression of the transcription factor, we assessed both cell lines for their expression of PLZF by immunoblot analysis. Consistent with a role for PLZF in the IFN response, the IFN-sensitive RCC1 cells expressed higher amounts of PLZF than the relatively IFN-insensitive ACHN cells ([Figure 1](#fig1){ref-type="fig"}B).Figure 1PLZF Regulates Sensitivity to IFNTo determine factors contributing to IFN sensitivity, two RCC cell lines, ACHN and RCC1, were analyzed for ISG expression and response to IFN treatment.(A) ISGs induced by 1000 IU/ml IFNα-2b at any one time point in either ACHN or RCC1 cells. Red indicates induced genes, yellow indicates no change, and green indicates repressed genes (top-left panel). The bar graph below shows the number of genes induced at least 1.5-fold for each sample. A total of 22 ISGs with higher and more persistent expression in the IFN-sensitive RCC1 cells is shown (top-right panel).(B) Immunoblot analysis of PLZF expression in ACHN and RCC1 cells in the presence or absence of IFNα. Data are representative of three independent experiments.(C) ISGs expressed in PLZF-inducible U937T cells, treated with IFNα for 6, 16, and 24 hr in the presence and absence of PLZF expression (24 hr after tetracycline withdrawal). The bar graph below shows the number of genes induced at least 2-fold for each sample.(D) Expression of select genes ([Table S4](#app2){ref-type="sec"}) was verified with SYBR Green real-time RT-PCR. Data are shown as mRNA expression normalized to the GAPDH RNA. Data were confirmed in three independent experiments.

We further investigated this correlation between IFN sensitivity and expression of PLZF by using a monocytic U937 cell line stably transformed with a tetracycline-inducible PLZF-expressing construct (U937T:PLZF45) ([@bib32]). The ISG expression profiles of U937T:PLZF45 cells with and without tetracycline and IFNα were examined. PLZF expression alone resulted in the induction of a subset of ISGs and this was further enhanced by IFNα ([Figure 1](#fig1){ref-type="fig"}C and [Table S2](#app2){ref-type="sec"}). The expression of representative ISGs was validated with real time RT-PCR ([Figure 1](#fig1){ref-type="fig"}D). Interestingly, an analysis of gene categories regulated by PLZF identified overrepresentation of immune response genes, particularly ISGs ([Tables S3--S5](#app2){ref-type="sec"}), suggesting a particular role for PLZF in mediating the immune response.

PLZF Is Required for the IFN-Mediated Antiviral Response {#sec2.2}
--------------------------------------------------------

To evaluate the contribution of PLZF to immune function, the IFN-mediated antiviral response was measured in embryonic fibroblasts (MEFs) derived from PLZF-deficient (*Zbtb16^−/−^*) mice. Wild-type MEFs showed 100-fold greater IFN-mediated protection to infection with Semliki Forest Virus (SFV) than *Zbtb16* ^−/−^ MEFs ( [Figure 2](#fig2){ref-type="fig"}A and [Figure S3](#app2){ref-type="sec"}). The role of PLZF in the in vivo IFN-mediated antiviral response was assessed by infectious challenge of *Zbtb16* ^−/−^ and wild-type neonatal mice. Mice were infected with SFV at ten times the half-maximal tissue culture infectious dose (TCID~50~), and resistance to the virus was measured as survival after infection. The survival curve of infected *Zbtb16* ^−/−^ mice closely parallels the wild-type, with all mice of both genotypes dead by 3.5 days after infection ([Figure 2](#fig2){ref-type="fig"}B) (p \> 0.05). Appropriately, IFN pretreatment of mice for 6 hr before exposure to SFV afforded significant protection to wild-type mice, with 60% of infected neonates (18 of 30) surviving past 22 days. In contrast, IFN pretreatment did not protect the *Zbtb16* ^−/−^ mice from SFV infection, with no survival beyond 6 days after infection ([Figure 2](#fig2){ref-type="fig"}B). Viral loads in the organs from *Zbtb16* ^−/−^ and wild-type neonatal mice were measured 48 hr after infection with SFV. Consistent with the survival results, viral titers in the organs of *Zbtb16* ^−/−^ mice, including the lung, thymus, spleen, heart and liver, were up to 1,000-fold greater than their wild-type littermates ([Figure 2](#fig2){ref-type="fig"}C).Figure 2PLZF Is Required for the IFN-Mediated Antiviral Response(A) Antiviral assay on wild-type (WT) and PLZF-deficient (*Zbtb16*^−/−^) MEFs infected with SFV for 48 and 72 hr. IFNα1 was added to cells at the indicated concentrations 16 hr prior to infection. The titers of IFNα required to protect cells from the cytopathic effects of SFV infection are expressed as percentage survival. Error bars represent 1 standard deviation (SD).(B) Survival after SFV infection of neonatal mice. WT or *Zbtb16*^−/−^ neonatal mice between 5 and 6 days of age were divided into two groups: either a control group for each genotype (without IFN pretreatment: WT, n = 11; *Zbtb16*^−/−^, n = 8) or an IFN pretreatment group (WT, n = 30; *Zbtb16*^−/−^, n = 12). The IFN pretreatment group was given 5000 IU IFNα; the control group was injected with PBS. After 6 hr, all mice were infected with SFV at 30× TCID~50~ and were monitored. Without IFN treatment, there was no significant difference in resistance to infection with SFV at 30× TCID~50~ in WT and *Zbtb16*^−/−^ neonatal mice (p \> 0.05, log-rank test). With IFN pretreatment, wild-type mice showed more resistance in response to SFV than *Zbtb16*^−/−^ mice (^∗∗∗^p \< 0.001, log-rank test).(C) Increased virus replication in *Zbtb16*^−/−^ mice. Neonatal mice from *Zbtb16^+/−^* matings were injected with IFNα1 and SFV between 5 and 6 days of age. Neonates were monitored for 72 hr, at which time they were killed and organs were collected. Viral titers were measured by CPE assay and expressed as mean log titer ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; and ^∗∗∗^p \< 0.001; *Zbtb16*^−/−^ neonatal mice (n = 7) versus their wild-type littermates (n = 8; Mann-Whitney rank sum tests).(D) *Zbtb16*^−/−^ mice also show increased susceptibility to lethal infections with EMCV. *Zbtb16*^−/−^ mice (n = 5) and WT littermate controls (n = 7) were injected i.p. with 500 pfu of EMCV and monitored for survival. *Zbtb16*^−/−^ mice died after a mean survival time of 4 days, whereas WT mice survived for a mean of 7 days (p = 0.009).

The observed immune impairment in *Zbtb16* ^−/−^ mice was not restricted to an increased susceptibility to infection by SFV. Wild-type and *Zbtb16* ^−/−^ mice had dramatically different susceptibility to infection with the encephalomyocarditis virus (EMCV). Intraperitoneal injection, with 500 plaque-forming units of EMCV, of 8- to 10-week-old mice showed that wild-type mice had significantly better survival over their *Zbtb16* ^−/−^ littermates ([Figure 2](#fig2){ref-type="fig"}D). These results show that PLZF is a key component of the innate immune response and is essential for resistance to virus infection in vivo.

PLZF Regulates Antiviral Effectors {#sec2.3}
----------------------------------

In order to characterize the mechanism by which PLZF elicits an antiviral state, we analyzed IFN production and ISG expression in wild-type and *Zbtb16* ^−/−^ mice. Notably, the serum IFN concentrations were not obviously deficient in infected *Zbtb16* ^−/−^ mice ( [Figure 3](#fig3){ref-type="fig"}A). This indicated that the observed virus susceptibility is independent of IFN production. The expression profile of a number of PLZF-dependent ISGs, identified in array experiments ([Figures 1](#fig1){ref-type="fig"}A and 1C and [Table S2](#app2){ref-type="sec"}), was investigated ex vivo and in vivo. Importantly, the induction of the antiviral gene *Oas1g* by IFN was impaired in primary *Zbtb16* ^−/−^ bone-marrow-derived macrophages (BMMs) ([Figure 3](#fig3){ref-type="fig"}B). Given that OAS1 is an established effector for the antiviral action of IFN, specifically against SFV ([@bib6], [@bib36]), we measured its expression in different organs after IFN treatment and SFV infection. The induction of *Oas1g* was markedly impaired in splenocytes isolated from the *Zbtb16* ^−/−^ mice ([Figures 3](#fig3){ref-type="fig"}C--3E). Similarly, the antiviral ISGs *Rsad2* (also termed *Cig5* or *Viperin*) and *Ifit2* (or *Ifi54*) were impaired in *Zbtb16* ^−/−^ BMMs ([Figure 3](#fig3){ref-type="fig"}B) and splenocytes (data not shown), or SFV-infected organs from *Zbtb16* ^−/−^ mice ([Figures 3](#fig3){ref-type="fig"}C--3E). In keeping with the specificity of the PLZF response, expression of the PLZF-independent but IFN-regulated CCL5 (RANTES) transcript was not affected ([Figure 3](#fig3){ref-type="fig"}B). These data suggest that the increased susceptibility of *Zbtb16* ^−/−^ mice is due to a specific defect in the induction of antiviral genes.Figure 3PLZF Regulates Antiviral Effectors(A) Serum IFN concentrations from neonatal wild-type (WT) and *Zbtb16*^−/−^ mice injected with IFNα, with and without SFV injection. IFN was measured after 48 hr by CPE reduction assay. Bar graphs show mean ± SD of five mice for each group.(B) IFN-induced ISG expression of the antiviral IFN effectors OAS1, RSAD2, and IFIT2, and the chemokines CXCL10 (IP-10) and CCL5 (RANTES) were measured in WT or *Zbtb16*^−/−^ BMMs after IFNα treatment for 6 hr. Data are shown as mRNA expression normalized to the 18S RNA. Bar graphs show mean ± SD of three independent experiments.(C--E) The mRNA expression of the chemokine CXCL10 (IP-10) and the antiviral ISGs OAS1, RSAD2, and IFIT2 was measured in predominantly NK cell-rich organs (spleen, liver, and lung) from WT and *Zbtb16*^−/−^ neonatal mice after IFNα treatment and SFV infection. RNA samples were analyzed for ISG expression with a custom ISG probe.Data are representative of three independent experiments (mean ± SEM; A--E).(F) PLZF expression correlates with IFIT2 induction in response to IFNα in WT and *Zbtb16*^−/−^ mice. PLZF expression was determined in multiple organs including thymus. Mice were then injected with PBS or IFNα (1 × 10^5^ IU), and after 8 hr, multiple organs were removed and RNA was extracted. IFIT1 and IFIT2 mRNA expression was analyzed by real-time RT-PCR, with a custom ISG probe (top panels). Data are representative of three independent experiments (mean ± SEM).

A direct comparison of PLZF-independent and -dependent genes was made by comparison of the closely related *Ifit1* and *Ifit2* genes. Both IFIT1 and IFIT2 are strongly induced by IFN or viral infecton and are impaired in STAT1-deficient mice. These two genes are reported to have contrasting expression patterns in different tissues ([@bib50]). Both genes contain ISRE binding sites in their promoter, but there is no PLZF-binding motif in the *Ifit1* promoter. Accordingly, *Ifit2* induction was lost in the absence of PLZF, whereas *Ifit1* was still induced by IFNα in *Zbtb16* ^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}F). Furthermore, analysis of the expression of PLZF in different tissues showed a strong correlation between PLZF expression and *Ifit2* induction in response to IFNα ([Figure 3](#fig3){ref-type="fig"}F). Hence, the different expression patterns of these two related ISGs probably depend upon their separate regulation by PLZF. Although expression of IFIT1 is largely independent of PLZF, a degree of PLZF dependence is noted in the lung of mice, suggesting that PLZF might still contribute indirectly to inducer-specific ISG regulation.

Interestingly, measurement of CXCL10 expression in the organs after IFN treatment only, or IFN treatment and SFV infection, revealed that the induction of CXCL10 by IFNα was impaired in primary *Zbtb16* ^−/−^ BMMs ([Figure 3](#fig3){ref-type="fig"}B). CXCL10 was also markedly impaired in splenocytes, liver, and lung isolated from the SFV-infected *Zbtb16* ^−/−^ mice ([Figures 3](#fig3){ref-type="fig"}C--3E). CXCL10 (or IP-10) has been associated with NK cell activity and the resulting protection from virus infection ([@bib5], [@bib51]). Therefore, an additional means by which PLZF might regulate sensitivity to virus, besides inducing direct antiviral effectors, could be a result of IFN-mediated activation of NK cells via ISGs such as CXCL10. This possibility was investigated.

NK Cell Activation Is Impaired in *Zbtb16^−/−^* Mice {#sec2.4}
----------------------------------------------------

Two recent reports have shown that PLZF affects NKT cell activity ([@bib27], [@bib40]). However, analysis of PLZF expression in immune cells with the human and mouse microarray database (Gene Expression Omnibus \[GEO\] accession number GSE 6887) revealed that PLZF was also expressed in human NK cells ([Figure S4](#app2){ref-type="sec"}). Furthermore, we demonstrated that PLZF was expressed in mouse NK cells by sorting different spleen lymphocyte populations with FACS (NK1.1^+^CD3^−^) and then analyzing their gene expression ( [Figure 4](#fig4){ref-type="fig"}A). This analysis shows comparatively little expression in CD3^+^NK1.1^−^ T cells and no detectable transcript in B cells. Consequently, we investigated the effect of the loss of PLZF on NK cell function. FACS analysis of splenocytes showed there were equivalent numbers of NK cells in wild-type and *Zbtb16* ^−/−^ mice, with NK cells constituting 2%--3% of total splenocytes ([Figure 4](#fig4){ref-type="fig"}B). We investigated the effector function of NK cells from wild-type and *Zbtb16* ^−/−^ mice by testing their cytolytic activity against the NK-sensitive target cell line YAC-1 ([@bib14], [@bib43]). After treatment with poly(I:C), which activates NK cells through the IFNα signaling pathway, *Zbtb16* ^−/−^ NK cells were impaired in their ability to spontaneously lyse YAC-1 cells ([Figure 4](#fig4){ref-type="fig"}C, top panel). Moreover, when activated in vivo with IFNα, the ability of *Zbtb16* ^−/−^ NK cells to subsequently lyse YAC-1 target cells was also markedly impaired ([Figure 4](#fig4){ref-type="fig"}C, bottom panel). These results demonstrate that PLZF is required for NK cell effector function and also suggest that PLZF may regulate the expression of target genes involved in NK cytolytic activity. Given that cytokine-induced activation of NK cells results in a dramatic increase in the expression of Granzyme B (GzmB), we examined the ability of poly(I:C) and IL-2 to induce GzmB protein expression in murine splenic NK cells. Mice were injected intraperitoneally with poly(I:C) or PBS, and splenic NK cells were analyzed after 24 hr for GzmB expression by flow cytometry. Wild-type spleens of poly(I:C)-injected mice had a markedly higher percentage of NK cells positive for GzmB than spleens of *Zbtb16* ^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}D). The reduced amount of GzmB is consistent with a reduced ability to lyse target cells. Activation of NK cells in vitro with IL-2 induced equivalent amounts of GzmB in either genotype (data not shown). Therefore, the role of PLZF in the induction of GzmB is through IFNα, rather than other cytokines.Figure 4NK Cell Activation Is Impaired in *Zbtb16*^−/−^ Mice(A) Expression of the gene encoding PLZF in mouse spleen lymphocytes. Quantitative RT-PCR analysis of PLZF transcripts, relative to the expression of 18S mRNA, in various sorted lymphocyte populations. Results are the means of three independent experiments (mean ± SD).(B) NK cell numbers in the spleens of *Zbtb16*^−/−^ and wild-type (WT) mice. NK cell populations (NK1.1^+^CD49b^+^) were assessed by flow cytometry. Data (mean ± SD) are representative of three experiments.(C) Diminished NK cell activity in *Zbtb16*^−/−^ mice. Splenocytes labeled with carboxy-fluorescein diacetate succinimidyl ester (CFSE) were incubated for 4 hr with NK-sensitive YAC-target cells at the indicated effector-to-target (E:T) ratios. Lysed cells were detected by 7-amino-actinomycin D (7-AAD) incorporation. Mice were injected intraperitoneally with 10 μg of poly(I:C) 24 h (top panel), or IFNα1 2 days (bottom panel) before splenocyte isolation. Data are representative of four independent experiments (mean ± SD).(D) WT and *Zbtb16*^−/−^ mice were injected i.p. with 50 μg poly(I:C) or PBS (control), and after 24 hr, splenic NK1.1^+^ CD3^−^ NK cell expression of intracellular Gzmb was analyzed by flow cytometry. Flow cytometry data representative of at least five independent experiments are shown in the WT, with a significant increase in the percentage of NK cells positive (mean ± SD) for Gzmb after poly(I:C) injection.

PLZF Directly Regulates the Promoters of a Subset of ISGs {#sec2.5}
---------------------------------------------------------

Next we sought to define the mechanism by which PLZF enhanced the expression of a specific subset of ISGs. Treatment of U937T:PLZF45 cells with the transcriptional inhibitor actinomycin D suggested that the induction of selected ISGs by PLZF is a primary transcriptional event ([Figure S5](#app2){ref-type="sec"}). Promoter regions from the PLZF-regulated transcripts *Rsad2* and *Ifit2* were fused to luciferase and activity was measured after IFN treatment. Overexpression of PLZF in RCC1 or ACHN cells produced a dose-dependent induction of the reporter promoters. This effect was further enhanced by IFNα treatment ( [Figures 5](#fig5){ref-type="fig"}A--5C). Correspondingly, induction of the *Rsad2* promoter was impaired in cells with PLZF expression reduced by RNA interference ([Figure 5](#fig5){ref-type="fig"}D). Reporter constructs confirm the requirement to colocate ISRE and PLZF-binding sites in the promoters of PLZF-regulated ISGs ([Figure S6](#app2){ref-type="sec"}). A direct association of PLZF with the promoters of *Rsad2* and *Ifit2* was demonstrated by chromatin immunoprecipitation assays in the RCC1 and U937T:PLZF45 cell lines. Moreover, the association of PLZF to the *Rsad2* and *Ifit2* promoters was dramatically enhanced by IFN treatment ([Figure 5](#fig5){ref-type="fig"}E and [Figure S7](#app2){ref-type="sec"}).Figure 5PLZF Directly Regulates the Promoters of a Subset of ISGs(A--C) Overexpression of PLZF in RCC1 and ACHN cells induces RSAD2 and IFIT2 promoter activity. RCC1 or ACHN cells were cotransfected with a PLZF expression plasmid and RSAD2-Luc or IFIT2-Luc promoter reporter constructs, then treated with IFNα1 (500 IU/ml of IFNα1). The luciferase values were obtained in at least three independent experiments.(D) Immunoblot analysis of PLZF in RCC1 cells expressing targeted or control miRNA (top panel). Luciferase assay for RSAD2 promoter induction in RCC1 cells expressing miRNAs targeting PLZF (PLZF1.3 and PLZF2.4) or the control miRNA targeting LacZ (LacZ) then stimulated with IFNα (bottom panel) is shown.Data are representative of three independent experiments (mean ± SD; A--D).(E) Chromatin from PLZF-inducible (FLAG-tagged) U937T cells grown in the presence or absence of tetracycline (24 hr) and IFNα (1,000 U/ml for 6 or 24 hr) was immunoprecipitated with a FLAG antibody. Promoters of PLZF-dependent RSAD2, IFIT2, and PLZF-independent IFI15 were amplified from the immunoprecipitated PLZF-FLAG chromatin with SYBR Green quantitative RT-PCR. Data represent the relative amount of genomic DNA from each promoter normalized to 10% input DNA at each point.

IFN Activates PLZF {#sec2.6}
------------------

The observed IFN-enhanced association of PLZF with select ISG promoters could occur through direct posttranslational modification of PLZF and/or modification of transcriptional cofactors. To investigate the former possibility, we immunoprecipitated PLZF from control and IFNα-treated U937T:PLZF45 cells and probed the acetylation or phosphorylation state of the protein by immunoblotting. Although acetylation has been reported to be important for DNA binding of PLZF ([@bib19]), no change in the acetylation state was detected (data not shown). However, PLZF was found to be phosphorylated at serine and tyrosine residues, with tyrosine phosphorylation correlating with temporal treatment with IFNα ( [Figure 6](#fig6){ref-type="fig"}A). PLZF encodes two types of conserved domain, a BTB domain at the N terminus and nine repeated zinc finger domains at the C terminus. Because BTB domains have been shown to be crucial for homodimerization and protein-protein interaction ([@bib13]), we chose to focus on residues within this domain. Through alignment of the amino acid sequence of PLZF with BTB domains from various other proteins and by analysis with prediction programs (NetPhos 2.0, Department of Systems Biology, Technical University of Denmark), several putative phosphorylated residues within the BTB domain of PLZF were identified along with residues previously shown to be crucial for PLZF to function as a transcriptional repressor ([Figures S8--S10](#app2){ref-type="sec"}). We mutated residues in PLZF to test their significance in the IFNα-mediated induction of the *Rsad2* promoter. This approach identified the tyrosine at position 88 and a serine residue at amino acid 76 to be important for induction of *Rsad2* ([Figure 6](#fig6){ref-type="fig"}C). Consistent with these promoter reporter assays, phosphorylation analysis of the full-length mutant protein (S76A) indicated that the residue at position 76 was the sole phosphoserine residue of importance in IFN-mediated activation ([Figure 6](#fig6){ref-type="fig"}B). Two additional mutations, R49D and L103E, which had previously been demonstrated to constitute important structural components on either surface of the BTB domain, had opposing effects upon ISG induction. As anticipated, the L103E mutation impaired activation of *Rsad2*. Surprisingly, mutation of R49 induced the *Rsad2* reporter. Although the structure of the charged pocket that surrounds the R49 residue had been demonstrated to be critical for PLZF to function as a transcriptional repressor, these results suggest that other residues of the BTB domain on the lateral surface, where L103 lies, may be more pertinent to the role of PLZF as a transcription inducer.Figure 6IFN Activates PLZF(A) Phosphorylation of wild-type PLZF after IFNα stimulation. PLZF-inducible U937T cells grown in the presence or absence of tetracycline for 24 hr and IFN for the times indicated were immunoprecipitated (IP) with a PLZF antibody and immunoblotted (IB) with phospho-Tyr Ab (top panel) or phospho-Ser Ab (bottom panel).(B) Serine76 is required for PLZF phosphorylation in response to IFNα. HeLa cells were transiently transfected with wild-type (WT) FLAG-PLZF or various mutant PLZF expression plasmids; this was followed by IFNα treatment, immunoprecipitation (IP) with the FLAG antibody, and immunoblotting (IB) with a phosphoserine or FLAG antibody, as indicated. The bar graph shows the proportion of phosphoserine residues on WT and mutant PLZF, treated with or without IFNα.(C) Luciferase assay for RSAD2 promoter induction in lysates of RCC1 cells transfected with wild-type (WT) or indicated mutant PLZF expression plasmids, followed by stimulation with IFNα. The values obtained from at least three independent transfection experiments were normalized to TK Renilla.(D) HeLa cells were transfected with PLZF expression and RSAD2 promoter reporter plasmids. The cells were then either left untreated or were treated with inhibitors of ERK (5 μM PD98059), JNK (1 μM SP600125), p38 (2.5 μM SB203580), Src (1 μM AZD0530), PI3K (1 μM AS-252424), or JAK2 (0.5 μM JAK2 inhibitor II); they subsequently underwent IFNα stimulation for 8 hr before RSAD2 promoter reporter activity in cell lysates was measured.(E) Luciferase assay for RSAD2 promoter induction in lysates of HeLa cells overexpressing PLZF and pretreated with different concentrations of JNK inhibitor, followed by IFNα stimulation. Data are representative of three independent experiments (mean ± SD; C--E).

To identify the kinase that phosphorylates PLZF, we conducted reporter assays (using *Rsad2*-luciferase) in cells treated with kinase inhibitors or cell lines defective in components of the IFN signaling pathway. Predictably, mutations in the JAK-STAT pathway led to the impairment of all IFN signaling for PLZF-regulated ISGs ([Figure S11](#app2){ref-type="sec"}). Treatment of HeLa cells with pharmacological inhibitors of ERK (PD98059), JNK (SP600125), p38 (SB203580), Src (AZD0530), PI3K (AS-252424), or JAK2 (JAK2 inhibitor II), followed by stimulation with IFN, points to JNK as a possible PLZF kinase ([Figures 6](#fig6){ref-type="fig"}D and 6E), or at least a critical kinase in the pathway, and supports the importance of serine phosphorylation of the protein ([Figure 6](#fig6){ref-type="fig"}B).

PLZF Regulates ISGs through Interaction with HDAC1 and PML {#sec2.7}
----------------------------------------------------------

IFN-enhanced association of PLZF with select ISG promoters could also occur through regulation of transcriptional cofactors. Accordingly, we sought to measure IFN-induced changes in known PLZF cofactors. Transcriptional repression by PLZF is sensitive to inhibitors of deacetylation, and PLZF physically interacts with both class I and II histone deacetylases (HDACs) via the BTB domain ([@bib1], [@bib10], [@bib11]). In accord with a requirement for HDAC activity for transcriptional activation of ISGs by PLZF, treatment of cells with the HDAC inhibitor trichostatin A (TSA) blocked induction of selected ISGs in the PLZF-inducible U937T:PLZF45 cells or BMMs ( [Figures 7](#fig7){ref-type="fig"}A and 7B). An association between the class I histone deacetylase HDAC1 and PLZF was shown by coimmunoprecipitation of overexpressed FLAG-tagged PLZF in HEK293 cells. Notably, an association with the class II histone deacetylase HDAC4 was not detected under the same conditions ([Figure 7](#fig7){ref-type="fig"}C). This association between PLZF and HDAC1 was confirmed with endogenous protein under more physiologically relevant conditions in primary BMMs ([Figure 7](#fig7){ref-type="fig"}D). As an additional measure of co-operation between PLZF and HDAC1, the effect of coexpressing PLZF and HDAC1 upon the *Rsad2* reporter was measured in IFN-responsive RCC1 cells. Appropriately, coexpression of PLZF with HDAC1 enhanced the induction of the ISG promoter by IFNα to a greater degree than that observed with either protein expressed alone. Moreover, treatment with TSA blocked the additive effect of PLZF and HDAC1 ([Figure 7](#fig7){ref-type="fig"}E).Figure 7PLZF Regulates ISGs through Interaction with HDAC1 and PML(A) Relative transcript levels of RSAD2, IFIT2, and IFI15, after tetracycline withdrawal for the PLZF-inducible U937T cells, treated with TSA prior to huIFN-α2b. RNA was extracted and ISG expression was measured by real time RT-PCR. Data are shown as RSAD2, IFIT2 and IFI15 RNA levels normalized to GAPDH RNA.(B) Transcript levels of RSAD2 and IFIT2 measured by real-time RT-PCR in wild-type (WT) and *Zbtb16*^−/−^ BMMs. Cells were treated with IFNα, TSA alone, or IFNα and TSA. Data are shown as RNA expression levels normalized to 18S RNA and are representative of three independent experiments (mean ± SEM; A and B).(C) Cell lysates prepared from HEK293T cells transiently transfected with FLAG-PLZF, immunoprecipitated (IP) with the FLAG antibody, and immunoblotted (IB) with anti-HDAC1 or anti-HDAC4.(D) WT and *Zbtb16*^−/−^ BMMs were incubated in the absence or presence of IFNα. Cell lysates were immunoprecipitated with PLZF antibody and immunoblotted with HDAC1 antibody.(E) RCC1 cells expressing PLZF and HDAC1 alone or in combination were stimulated with IFNα, TSA alone, or IFNα and TSA. Relative RSAD2 promoter activity was determined by activity of RSAD2 luciferase assay and normalization to TK Renilla. Data are representative of three independent experiments (mean ± SD).(F) HeLa cells were transiently transfected with FLAG-PLZF; this was followed by IFNα treatment, immunoprecipitation with the FLAG antibody, and immunoblotting with a PML or PLZF antibody, as indicated.(G) WT and *Zbtb16*^−/−^ BMMs were incubated in the absence or presence of IFNα, immunoprecipitated with PLZF antibody, and immunoblotted with PML antibody.(H) Confocal images of RCC1 cells transiently expressing PLZF-CFP with and without IFNα treatment. Arrows indicate the colocalization of PLZF with PML. Images are representative of four independent experiments.

A second transcription factor reported to associate with PLZF is the promyelocytic leukemia protein (PML) ([@bib26], [@bib38]). Of relevance to this study, PML mediates the formation of nuclear bodies that are crucial in the IFN response. More directly, it has been established that the antiviral response is reduced in PML-deficient MEFs ([@bib12]). To determine whether PML is a cofactor in PLZF-mediated activation of ISGs, we performed coimmunoprecipitation assays on lysates from the IFN-responsive HeLa cells, overexpressing PLZF-tagged constructs, or on endogenous PLZF from primary BMMs. PLZF was found to interact with PML in both cell types after IFNα treatment ([Figures 7](#fig7){ref-type="fig"}F, 7G; [Figures S12 and S13](#app2){ref-type="sec"}). Importantly, PML has been demonstrated to alter the cellular location of PLZF ([@bib26]). To show whether the association between PLZF and PML, detected by immunoprecipitation, correlated with colocalization of the proteins within nuclear bodies, we performed confocal microscopy with fluorescently tagged proteins in RCC1 cells treated with or without IFNα. Indirect immunofluoresence confirmed that PLZF localized with PML after IFN stimulation ([Figure 7](#fig7){ref-type="fig"}H). The reported induction of PML by IFN does not account for the observed colocalization, given that the amounts of PML did not significantly increase over the duration of this experiment ([Figure S14](#app2){ref-type="sec"}). Together, these data show that IFN treatment induces phosphorylation of PLZF, plausibly by JNK, and interaction with both HDAC1 and PML to mediate association of the complex with PLZF-binding sites in gene promoters to induce specific ISGs.

Discussion {#sec3}
==========

Recent studies have shown that type I IFN signaling is more complex than initially recognized, activating different specific signals and patterns of gene expression ([@bib53]). The response via the canonical JAK-STAT pathway alone is not sufficient to explain all the biological effects of type I IFN. Accordingly, other kinases, including PI3K and MAP kinase, lead to the activation of additional transcription factors such as NF-κB, AP-1, IRFs, and PU.1, which interact with STATs at interferon-stimulated response elements (ISREs) via ISGF3 or other IRFs to regulate ISGs. We showed that the transcription factor PLZF is a regulator of the IFN response. PLZF induced a specific subset of ISGs with PLZF-binding sites in proximity to ISRE. Gene array, chromatin immunoprecipitation (ChIP) assays, and promoter reporter experiments demonstrated that PLZF directly occupied these select promoter sequences and that this activity was IFN dependent. In this study, analysis of all genes induced by PLZF showed a predominance of ISGs, explicitly implicating PLZF in positively modulating the IFN pathway.

Although PLZF has been designated as a transcriptional repressor, our observation that PLZF promotes ISG transcription is not without precedence ([@bib28], [@bib41]). The mechanism for transcriptional repression by PLZF is thought to involve constraint of the accessibility of the gene to transcriptional machinery, via chromatin remodeling by acetylation involving the nuclear corepressor complex (NCoR) and HDACs, particularly HDACs 1 and 4 ([@bib10], [@bib11], [@bib19], [@bib24], [@bib33]). Although HDACs are generally considered as corepressors, HDAC1 could serve as a coactivator for the glucocorticoid receptor ([@bib37]). More relevant to our findings, we and others found that inhibition of HDAC1 perturbed IFN-induced transcription and antiviral responses. Moreover, data generated from HDAC1-deficient cells show that this protein is required for the efficient activation of ISGs ([@bib9], [@bib56]). Also, HDAC1 but not HDAC4 associated with STAT1 and STAT2 to positively activate expression of the ISG3-dependent transcriptional response. Correspondingly, we detect an association between PLZF and HDAC1, not HDAC4, upon stimulation with IFNα, leading us to propose that HDAC1 is key to PLZF\'s role as a transcriptional enhancer. Similarly to HDAC1, a second PLZF cofactor, PML, is indispensable for the IFN response ([@bib20]). Appropriately, PML is induced by IFN through an ISRE and an IFN-γ activation site (GAS) motif in its promoter, and the number and intensity of nuclear bodies increase in response to IFN ([@bib45]). More directly, it has been established that the antiviral response is reduced in PML-deficient MEFs ([@bib12]). We demonstrate here that PLZF and PML associate and that this interaction is also modulated by IFN.

Although the precise mechanism modulating the association between PLZF and its cofactors has not been established, it is predicted to be mediated by the BTB domain of PLZF ([@bib35]). This domain acts as a homodimerization motif that is essential for the repressor function of PLZF and its localization in nuclear bodies. ([@bib34]) Our results suggest that this domain is also key for its transcriptional enhancer function. However, our observations indicated differences in how the BTB domain mediates repressor or enhancer activities of PLZF. Mutation of the residue at position 49 in the BTB domain of PLZF, shown to be essential for repressor activity, had the contradictory effect of further enhancing ISG expression. Mutation of another key structural residue, on the lateral face of the BTB domain at position 108, recapitulated the loss of function as a repressor. This implies that different regions of PLZF mediate repressor or enhancer functions. Because we found an interaction between PLZF, PML, and HDAC1 only after IFN stimulation, it seems likely that IFN signaling affects the state of one or all of these proteins. Informatively, the apparent paradoxical function of HDAC1 as a corepressor or coactivator appears to be regulated by acetylation of the protein itself ([@bib34]). It is also reported that PLZF is both acetylated and phosphorylated ([@bib3], [@bib19]). In this study, PLZF was found to be phosphorylated at serine and tyrosine residues in response to IFN, and we identified a serine residue (Ser76) that resides in the BTB domain of PLZF and that was important for PLZF-mediated ISG induction, thereby implicating a serine kinase in PLZF activation. Accordingly, kinase inhibitor studies implicate the serine kinase JNK as a potential activator of PLZF.

Recognition of PLZF-binding sites in proximity to ISRE suggests cooperation between canonical IFN transcription factors and PLZF. Only promoters containing both regulatory elements show both PLZF- and IFN-dependent expression. Experiments in STAT1-deficient cells demonstrate that this factor is required for PLZF-dependent transcriptional induction, as expected in IFN signaling. A direct comparison of PLZF-independent and -dependent genes demonstrated that tissue-specific expression patterns of the closely related ISGs IFIT1 and IFIT2 may be determined by PLZF. We demonstrated that PLZF associates with other essential cofactors, PML and HDAC1. Consequently, we propose a model whereby PLZF functions to stabilize a transcription complex that minimally includes STATs, HDAC1, and PML to mediate the expression of specific ISGs.

Although only a subset of ISGs is regulated by PLZF, the observed impairment is physiologically critical because it is sufficient to severely compromise the antiviral immune response. We showed this immune impairment was due to direct defects in key IFN-mediated antiviral factors and to indirect mechanisms that modulate NK cell activity. The reduced viral load in the presence of PLZF and IFN suggests that IFN-improved survival after SFV infection requires PLZF. This correlates with regulation of the expression of the antiviral mediator OAS1. OAS1 combined with the ribonuclease L (RNaseL) constitutes an antiviral RNA decay pathway previously demonstrated to regulate SFV infection ([@bib57]). Impaired induction of other ISGs such as IFIT2 and RSAD2, which have recently been shown to function as antiviral effectors, was also found ([@bib6]). Other ISGs identified as having impaired induction in *Zbtb16* ^−/−^ cells, most pertinently CXCL10, do not have a direct antiviral function. CXCL10 has been demonstrated, with other chemokines, to regulate NK cell function ([@bib5]). A recent study comparing wild-type and *Cxcl10* ^−/−^ mice has shown that CXCL10 expression promotes protection from coronavirus-induced neurological and liver disease ([@bib54]). Furthermore, a study using *Cxcl9* ^−/−^ and *Cxcl10* ^−/−^ mice has found that these chemokines are critical for the control of Herpes Simplex Virus infection through mobilization of NK cells and CTL to sites of infection ([@bib51]). IFN has an established role in the function of NK cells and influences NK activation during viral infection. Defects in NK cell activity, such as decreased production of IFN, also render mice more susceptible to viral infection ([@bib30]). However, impaired NK cell function in *Zbtb16* ^−/−^ mice is independent of IFN production. Instead, we propose that the observed defect in NK cell activity in the *Zbtb16* ^−/−^ mouse is due to impairment of specific ISGs, with CXCL10 identified as a likely candidate. *Zbtb16* ^−/−^ mice show a marked decrease in CXCL10 expression in NK cell-rich organs, and such a decrease may lead to impaired mobility of NK cells, and therefore ineffective viral clearance. IFN-induced activation of NK cells resulted in potent cytotoxicity associated with a dramatic increase in GzmB. GzmB expression is essential for eliciting NK cell cytotoxic function and is responsible for the rapid induction of caspase-dependent apoptosis. Previous studies have demonstrated GzmB is an ISG ([@bib8], [@bib55]). However, the regulation of GzmB expression is not understood. Intriguingly, the GzmB promoter contains a binding site for PLZF, raising the possibility that PLZF directly regulates GzmB transcription. The findings here suggest that IFN-mediated activation of NK cells is regulated by PLZF.

Until recently, PLZF had not been ascribed any role in immune regulation. However, two recent reports demonstrate that PLZF is also expressed in NK T cells and that the transcription factor is essential to the development of these cells ([@bib27], [@bib40]). Here, we showed that PLZF is also expressed in NK cells and provide evidence that PLZF is pivotal in the IFN-dependent activation of NK cells. The finding described here provides evidence that PLZF plays an important role in innate immunity via modulation of the IFN response. PLZF regulates a key subset of ISGs with consequences for the archetypal function of IFN, to instigate resistance to virus infection.

Experimental Procedures {#sec4}
=======================

Cell Lines and Treatments {#sec4.1}
-------------------------

RCC1 ([@bib7]) and ACHN (ATCC CRL-1611) cells were maintained in RPMI and DMEM, respectively. The U937T:PLZF45 inducible PLZF system was previously described ([@bib32]) and is based on the U937T autoregulatory tet-off system, in which withdrawal of tetracycline leads to gene expression. Actinomycin D was added to cells at a final concentration of 5 μg/ml for 8 hr prior to IFN treatment. Trichostatin A was added to cells at a final concentration of 25 ng/ml for 8--24 hr prior to IFN treatment. We obtained spleen macrophages and BMMs from age-matched WT and *Zbtb16* ^−/−^ mice as previously described ([@bib4]). BMMs were isolated from mice and cultured as described ([@bib48]). Cells were plated at a density of 1 × 10^7^ cells/plate and were cultured for an additional 24 hr without colony-stimulating factor 1. Cells were treated with 500--1000 IU/ml of IFNα1, then collected at 3, 6, and 9 hr for gene expression analysis.

Microarray {#sec4.2}
----------

Previously obtained data of Affymetrix HG_U95Av2 expression profiles 24 and 48 hr after PLZF expression, performed in biological triplicate, were analyzed for genes with significant changes in gene expression as a result of PLZF expression with Significance Analysis of Microarrays (SAM; [http://www-stat.stanford.edu/∼tibs/SAM/](http://www-stat.stanford.edu/~tibs/SAM/)) ([@bib32], [@bib52]). RNA was extracted from control and IFN-treated U937T PLZF cells with Trizol reagent (Invitrogen). Labeling and hybridization to the custom ISG cDNA array were performed as described previously ([@bib16], [@bib44]). Analysis was performed with GeneSpring 5.0 (Agilent). Data were first normalized with LOWESS normalization for each experiment, and then each array was normalized to the intensity of GAPDH expression so that intensities across samples could be compared. Genes with unreliable expression intensities below 300 for the induced sample (IFN-treated, PLZF-expressing, or PLZF-expressing IFN-treated) were discarded from further analyses. Data were filtered for genes induced over 2-fold in PLZF-expressing cells, and genes whose expression was 2-fold higher with PLZF and IFN treatment over IFN treatment alone were defined as PLZF responsive. PLZF-responsive genes were partitioned into seven sets with K-means cluster analysis with a standard correlation and 100 iterations.

Quantitative Real-Time PCR {#sec4.3}
--------------------------

Total RNA was extracted from cells with Trizol reagent (Invitrogen), and cDNA was produced with random hexamer primers and Superscript III reverse transcriptase (Invitrogen). PCR was performed on an Applied Biosystems 7700 Prism real-time PCR machine with the manufacturer\'s SYBR green kit and instructions (Applied Biosystems). Expression analysis of human samples by real-time PCR was done with the primers listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. The 2^-ΛΛCt^ method was used for analysis with the untreated sample as the reference. Quantitative-PCR (Q-PCR) was performed in mouse samples. Predeveloped TaqMan probe/primers for RASD2, IFIT1, IFIT2, 2′-5′OAS, CXCL10, and CCL5 (Applied Biosystems) were used for calculation of the threshold cycle numbers that were transformed with the cycle threshold and relative value method as described by the manufacturer and were expressed relative to 18S ribosomal RNA. Results are expressed as relative gene expression for each target gene.

Bioinformatic Analysis {#sec4.4}
----------------------

To elucidate functional similarities among the genes induced by PLZF, we mined gene ontologies by using the Expression Analysis Systematic Explorer (EASE) Functional Annotation Tool Suite. Promoters were retrieved with Promoser and potential binding sites were identified with MatInspector (Genomatix Suite). Overrepresented motifs were identified with MEME and JASPAR ([@bib2], [@bib47]) with the "-zoop" option, which indicates "zero or one occurrence per sequence," and motif width was set between 6 and 15 bp. Gene promoters that contain the ten most frequently occurring motifs were selected for further analysis. For each of these, the positional specific scoring matrix (PSSM) generated by MEME was searched against the TRANSFAC database with the MALIGN algorithm ([@bib22]). The PLZF BTB domain was analyzed with the Conserved Domain Database and TCoffee. PLZF protein sequence was run by the NetPhos 2.0 server program for predictions of serine, threonine, and tyrosine phosphorylation sites. The above bioinformatic analyses used the web programs listed in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Chromatin Immunoprecipitation Assay {#sec4.5}
-----------------------------------

Chromatin immunoprecipitation assays were done in accordance with the manufacturer\'s instructions (Upstate Biology). The presence of the target gene promoter sequences in both the input DNA and the recovered DNA immunocomplexes was detected by quantitative PCR. The antibodies used for ChIP were against PLZF (Calbiochem) and FLAG M2 (Sigma). After reversal of the crosslinking, DNA was recovered by phenol-chloroform extraction and ethanol precipitation and then used in a PCR. The sequences of the primers used for the PCR are listed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. PCR for IFIT2, RSAD2, and ISG15 was performed with a Sybr Green PCR mastermix (AP Biotech) on an iCycler PCR machine (Biorad).

Immunoprecipitation and Immunoblotting Analysis {#sec4.6}
-----------------------------------------------

For immunoprecipitation, cells were lysed with triple detergent lysis buffer and incubated with antibodies (anti-PLZF and anti-FLAG) as indicated. Antibody complexes were isolated with protein A/G-agarose beads (Pharmacia Biotech), and immunocomplexes were analyzed by SDS-PAGE and immunoblotting with anti-phospho Ser, anti-phosphoTyr (Upstate), anti-PLZF, anti-PML, anti-HDAC1, or anti-HDAC4. Expression of PLZF was assessed by immunoblotting with anti-PLZF (Calbiochem). Protein bands were detected and quantified on a Li-Cor Odyssey infrared imaging system or exposure of the membrane to BioMax autoradiographic film (Kodak).

RNAi-Mediated PLZF Knockdown {#sec4.7}
----------------------------

Knockdown of PLZF was induced by transfection of BLOCK-iT Pol II miR RNAi Expression Vector (RNAi PLZF plasmids targeting two different sequences in PLZF, and LacZ as control). The miRNA (plzf) target sequences were: miRNAi plzf13 (437-456), 5′-TGCTGTATAGTGTTGACTATTGCGGTTTTGGCCACTGACTGACCGCAATAGTCAACACTATA-3′; and miRNAi plzf24 (1116-1135), 5′-TGCTGTAGTGTAGCTCCCTAGCACGTTTTGGCCACTGACTGACGTGCTAGGGAGCTACACTA-3′. Starting 24 hr after transfection, untransfected cells were eliminated by culturing the cells in the presence of 10 μg/ml blasticidin for 10--14 days. Total cellular RNA was isolated and whole-cell lysates were used for immunoblotting. The efficiency of the knockdown was assessed at the protein level by immunoblotting.

Transfection Assay and Luciferase Assays {#sec4.8}
----------------------------------------

The RASD2 luciferase reporter was provided by K. Fitzgerald ([@bib42]), and the IFIT2 luciferase reporter was cloned by PCR. All plasmids used in the transfection assay were prepared with the endotoxin-free plasmid Maxi-kit (QIAGEN). A total 2 × 10^5^ RCC1 or ACNH cells were incubated overnight. The wild-type and mutant RSAD2 promoter reporter gene vector (1 μg), along with 0.2 μg of a phRL-TK Synthetic Renilla expression vector, were transfected into cells with Fugene 6 (Roche). After transfection for 24 hr, the cells were harvested and lysed. Luciferase activity was generated with luciferase substrate and read out in opaque 96-well plates with a plate-reading luminometer. phRL-TK Synthetic Renilla was cotransfected for normalization of transfection efficiency. Experiments were performed in triplicate.

Immunofluorescence {#sec4.9}
------------------

Approximately 1 to 2 × 10^5^ cells were seeded in Chamber slides (Lab-Tek II, Nalge Nunc International). The 60%--80% confluent culture of cells was treated with IFNα for 2--4 hr. The cells were then fixed with 4% paraformaldehyde and blocked with CAS blocking solution (Zymed). The cells were incubated with the PML (Santa Cruz) primary antibody, incubated sequentially with FITC-conjugated anti-rabbit secondary antibodies (Molecular Probes), and analyzed by fluorescence or confocal microscopy (Leica Instruments).

Antivirus Assay {#sec4.10}
---------------

Wild-type and *Zbtb16* ^−/−^ primary MEFs were generated. Cells were seeded into 96-well plates at 1 × 10^4^ cells/well and incubated overnight, treated with serial dilutions of mouse IFN-α1 for 16 hr, and challenged with SFV virus (10^5^--10^7^ plaque-forming units \[pfu\]) for an additional 48 and 72 hr. Viral titers were determined as the dilution at which 50% death occurred and are expressed as log~10~ titers or as "fold dilution" ([@bib15]). Cells were fixed with cold methanol and stained with crystal violet, before optical density at 620 nm was read.

Viral Infection of Mice {#sec4.11}
-----------------------

Pups between 5 and 6 days of age were injected intraperitoneally (i.p.) with 50 μl SFV at 10×, 30×, and 100× TCID~50~, determined by CPE bioassay of mouse L929 cell cultures. Some mice were preinjected with mouse IFNα 6 hr before viral infection. The mouse IFNα titer was verified in a CPE-reduction bioassay. Experiments with wild-type and *Zbtb16* ^−/−^ mice used littermate controls and were conducted by researchers "blinded" to experimental conditions, with genotypes being determined after completion of the experiments. Mice were monitored at 3−6 hr intervals and resistance was recorded for up to 3 weeks. Viral titers of each organ were measured at day 3 of SFV infection and IFN pretreatment ([@bib15]). For in vivo infections with EMCV, 500 pfu were injected i.p. into *Zbtb16* ^−/−^ mice and wild-type littermate controls. These studies were approved by the Monash University Monash Medical Centre A Animal Ethics Committee (Melbourne, Australia).

Serum Interferon Assays {#sec4.12}
-----------------------

Serum samples from neonatal mice were diluted in semi-log~10~ steps in duplicate into 96-well plates containing L929 cell monolayers. The medium was removed 16 hr later and SFV added at a concentration of 10× TCID~50~ in fresh RPMI medium. Plates were subsequently incubated for 48−72 hr, after which they were assigned scores for CPE. This assay measures the activity of all type I and type II interferons. The interferon activity (IU/ml) was calculated by comparison of the titer of the sample with a laboratory IFNα standard calibrated to the National Institutes of Health reference standard Ga02-901-511.

Cytotoxicity Assay {#sec4.13}
------------------

This flow cytometric method, previously described by [@bib29], entails labeling effector cells with carboxy-fluorescein diacetate succinimidyl ester (CFSE) so that they could be discriminated from target cells, then adding 7-amino-actinomycin D (7-AAD) so that killed targets could be labeled. Mice were injected i.p. with 0.1 ml of PBS containing poly(I:C) (10 μg/mouse) or IFNα (1 × 10^5^ IU/mouse), and splenocytes were harvested after 24 or 60 hr, respectively, and labeled with CFSE. In vitro NK lysis was monitored by incubation of different numbers of CFSE-labeled effector cells with 1 × 10^4^ target cells (YAC-1 cells) at 37°C for 4 hr. In parallel, target cells were incubated alone for basal apoptosis measurement. Immediately before analysis, 1 μg/ml (final concentration) of 7-AAD was added to each sample and incubated for 20 min. The percentage of apoptotic (7-AAD^lo^+7-AAD^hi^) cells is used for calculating the percentage of specific lysis according to the following formula: % specific lysis = 100 × (% sample lysis -- % basal lysis)/(100 − % basal lysis). Sample lysis is the cell lysis in the presence of effectors at a given E:T ratio, and basal lysis is the cell lysis in the absence of effectors.

Cell Isolation and Stimulation {#sec4.14}
------------------------------

Spleens were harvested and single-cell suspensions were generated. Red blood cells were lysed and the cells were washed in RPMI medium. For in vitro cytokine stimulation, splenocytes were plated at 10 × 10^6^/ml in 24-well plates in 1000 U/ml IL-2. Cells were harvested by pipetting with cold PBS after 48 hr and analyzed by flow cytometry. For cell sorting, splenocytes were surface stained with anti-NK1.1, anti-CD3, and anti-B220 (BD Biosciences PharMingen), and CD3^+^NK1.1^−^, CD3^−^NK1.1^+^, or B220 cells were isolated by cell sorter (routinely ≥99% pure).

Intracellular Staining and Flow Cytometry {#sec4.15}
-----------------------------------------

Splenocytes or tissue mononuclear cells were stained for surface markers (NK1.1) and intracellular Gzmb as described (eBioscience Foxp3 staining protocol) with directly conjugated Gzmb (1:400 dilution) monoclonal antibodies. Sample data were acquired on a Cytek-modified FACScan (BD) flow cytometer, and isotype controls were used to set quadrant gates.

Accession Numbers {#app3}
=================

Microarray data are available from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under accession number GSE 16197.

Supplemental Data {#app2}
=================

Document S1. Supplemental Experimental Procedures, Five Tables, and Fourteen Figures

We thank K. Fitzgerald for the RASD2-luc constructs, P. Hertzog and P. Fitzgerald-Bocarsly for helpful advice, and N. de Weerd, S. Samarajiwa, and J. Gould for mouse IFNα and SFV virus. We thank I. Harper, S. Firth, and C. Lo (Monash Micro Imaging) for the confocal microscopic analysis and M. Gantier, D. Wang, D. Wu, and J. Ou for technical assistance. We also thank F. Cribbin for critical reading and preparation of the manuscript. This work was supported by grants from the National Health and Medical Research Council of Australia (436814 to B.R.G.W.) and the National Institutes of Health (P01 CA062220 and R01 AI034039 to B.R.G.W.).

Supplemental Data include Supplemental Experimental Procedures, 5 tables, and 14 figures and can be found with this article online at <http://www.cell.com/immunity/supplemental/S1074-7613(09)00236-2>.

[^1]: These authors contributed equally to this work

[^2]: Present address: Gene Expression Omnibus, National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD 20892, USA

[^3]: Present address: RNA Therapeutics Department, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA

[^4]: Present address: Malaghan Institute of Medical Research, Wellington, New Zealand
